Genocea Biosciences Inc (GNCA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Genocea Biosciences Inc (GNCA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH141232D
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Genocea Biosciences Inc (Genocea), formerly Genocea Inc is a vaccine development company that discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses antigen lead acquisition system, a proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. Its product pipeline includes GEN-003, a therapeutic vaccine or immunotherapy used for the treatment of genital herpes infections; GEN-004, used in preventing pnemococcus infections; GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and HSV-PX. The company also provides treatment for pneunococcus, chlamydia, and malaria. Genocea is headquartered in Cambridge, Massachusetts, the US.

Genocea Biosciences Inc (GNCA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Genocea Biosciences Secures Funds from Hercules Technology 12

Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 13

Genocea Biosciences Raises USD0.4 Million In Venture Financing 14

Genocea Biosciences Raises USD30 Million In Series C Financing 15

Genocea Biosciences Secures USD35 Million In Series B Venture Financing 17

Partnerships 19

Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 19

Genocea Biosciences Enters into Agreement with US Oncology Research 20

Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

Licensing Agreements 24

Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 24

Equity Offering 25

Genocea Biosciences Raises USD50 Million in Public Offering of Shares 25

Genocea Biosciences Raises USD52 Million in Public Offering of Shares 27

Genocea Biosciences Raises USD2 Million in Private Placement of Shares 29

Genocea Biosciences Withdraws Public Offering of Shares 31

Genocea Biosciences Completes IPO For USD66 Million 32

Genocea Biosciences Inc-Key Competitors 34

Genocea Biosciences Inc-Key Employees 35

Genocea Biosciences Inc-Locations And Subsidiaries 36

Head Office 36

Recent Developments 37

Financial Announcements 37

Aug 09, 2017: Genocea Biosciences Reports Second Quarter 2017 Financial Results 37

May 04, 2017: Genocea Reports First Quarter 2017 Financial Results 38

May 04, 2017: Genocea Biosciences Q1 net loss increases 39

Feb 16, 2017: Genocea Reports Fourth Quarter and Year-End 2016 Financial Results 40

Nov 03, 2016: Genocea Reports Third Quarter 2016 Financial Results 42

Aug 04, 2016: Genocea Reports Second Quarter 2016 Financial Results 44

May 05, 2016: Genocea Reports First Quarter 2016 Financial Results 46

Feb 11, 2016: Genocea Reports Fourth Quarter and Year-End 2015 Financial Results 48

Corporate Communications 51

Mar 06, 2017: Howard Mayer, M.D., of Shire, Joins Genocea Biosciences' Board of Directors 51

Jun 09, 2016: Genocea Appoints Ron Cooper to Board of Directors 52

Clinical Trials 53

Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy 53

Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016 55

Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial 56

Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits 57

Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 58

Jun 09, 2016: Genocea Showcases Potential Of Recombinant Protein-based Vaccine GEN-004 At ASM Microbe 2016 59

Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing 60

Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Figures

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Genocea Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Genocea Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Genocea Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Genocea Biosciences Secures Funds from Hercules Technology 12

Genocea Biosciences Secures USD16.09 Million in Venture Funding from Auriga Partners 13

Genocea Biosciences Raises USD0.4 Million In Venture Financing 14

Genocea Biosciences Raises USD30 Million In Series C Financing 15

Genocea Biosciences Secures USD35 Million In Series B Venture Financing 17

Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 19

Genocea Biosciences Enters into Agreement with US Oncology Research 20

Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 21

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 22

Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 24

Genocea Biosciences Raises USD50 Million in Public Offering of Shares 25

Genocea Biosciences Raises USD52 Million in Public Offering of Shares 27

Genocea Biosciences Raises USD2 Million in Private Placement of Shares 29

Genocea Biosciences Withdraws Public Offering of Shares 31

Genocea Biosciences Completes IPO For USD66 Million 32

Genocea Biosciences Inc, Key Competitors 34

Genocea Biosciences Inc, Key Employees 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Genocea Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16143
Site License
USD 500 INR 32285
Corporate User License
USD 750 INR 48428

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com